A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

Across cohorts, only patients with SDH-mutant GIST experienced prolonged disease control. Despite evidence of target engagement, patients enrolled to all other cohorts had short PFS, suggesting rapid adaptation to ATR inhibitor monotherapy. Among these patients, those with tumors expressing SLFN11 during berzosertib exposure derived the most clinical benefit.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-10-25
DOI
https://doi.org/10.1158/1078-0432.ccr-24-1867
Citations
7
Primary Topic
RNA regulation and disease
Type
article
Field-Weighted Citation Impact
1.64

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

Oladapo Yeku, Alona Muzikansky, James M. Cleary, Colin D. Weekes et al.
7 citations
Clinical Cancer Research
RNA regulation and disease
1.64
article

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

Oladapo Yeku, Alona Muzikansky, James M. Cleary, Colin D. Weekes, Lee Zou, Aparna R. Parikh, Geoffrey Ira Shapiro, Daniel E. McLoughlin, Jong Chul Park, Andrea J. Bullock, T. Khanh, Bose Kochupurakkal, Xin Gao, Gregory M. Coté, Michael L. Cheng
article en
7 citations

Abstract

Across cohorts, only patients with SDH-mutant GIST experienced prolonged disease control. Despite evidence of target engagement, patients enrolled to all other cohorts had short PFS, suggesting rapid adaptation to ATR inhibitor monotherapy. Among these patients, those with tumors expressing SLFN11 during berzosertib exposure derived the most clinical benefit.

Clinical Cancer ResearchVol. 31(1)
Beth Israel Deaconess Medical Center (US), Harvard University (US), Duke University (US), University of California, San Francisco (US), Massachusetts General Hospital (US), Dana-Farber Cancer Institute (US), Center for Cancer Research (US), Duke University Hospital (US)
Mass General Cancer Center
Good health and well-being
Openalex Percentile: Top 16%
RNA regulation and disease
1.64
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.